Salix Pharmaceuticals is nearing Food and Drug Administration approval of a bowel cleansing prep for colonoscopy.

The FDA granted an approvable letter for MoviPrep, which would be available by prescription. However, Salix said final FDA approval depends on resolving of “certain manufacturing deficiencies”, according to Bill Forbes, vice president of research and development, and chief development officer for Salix. He said Salix is working with Norgine B.V., the European pharmaceutical firm from which it has licensed the product to resolve the problems.

Salix wants to launch the product this year, Forbes added.